Kazanietz M G, Enero M A
Catedra de Farmacología, Facultad de Farmacia y Bioquímica, UBA, Instituto de Investigaciones Farmacológicas, CONICET, Buenos Aires, Argentina.
Naunyn Schmiedebergs Arch Pharmacol. 1989 Sep;340(3):274-8. doi: 10.1007/BF00168510.
The effect of pretreatment with the beta-2-selective adrenoceptor agonist, (+/-)-clenbuterol (0.3 mg/kg, twice daily, 14 days) on prejunctional alpha-2- and beta-adrenoceptors was studied in rat atria. When atria from non-pretreated rats had been preincubated with (3H)-noradrenaline, (-)-isoprenaline (0.02 to 4.0 microM) did not affect tritium overflow evoked by stimulation of the cardioaccelerant nerves, but a higher concentration (40 microM) decreased it. Blockade of prejunctional inhibitory alpha-2-adrenoceptors by yohimbine (0.03, 0.3 and 0.8 microM) enhanced the overflow of tritium. In the presence of yohimbine, isoprenaline (1.2 microM) significantly increased stimulation-induced transmitter overflow, suggesting that in rat atria the facilitatory effect of isoprenaline mediated via prejunctional beta-adrenoceptors, is masked by the dominant influence of inhibitory alpha-2-adrenoceptors. (-)-Propranolol (0.1 microM) prevented the isoprenaline-induced increase in atrial rate and the isoprenaline-induced enhancement of transmitter release in the presence of yohimbine (0.3 microM), but did not modify by itself the stimulation-induced efflux of tritium, suggesting that neuronally released noradrenaline failed to activate facilitatory prejunctional beta-adrenoceptors. When atria from clenbuterol-pretreated rats had been preincubated with 3H-noradrenaline, the facilitatory effect of yohimbine 0.03 and 0.3 microM was markedly enhanced and, in this case, isoprenaline (1.2 and 12.0 microM) failed to cause its facilitatory effect in the presence of the alpha-2-adrenoceptor antagonist. Propranolol did not modify the facilitatory effect of yohimbine. No changes in the isoprenaline-induced increase in atrial rate were observed in clenbuterol-treated rats.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了β₂选择性肾上腺素能受体激动剂(±)-克伦特罗(0.3毫克/千克,每日两次,共14天)预处理对大鼠心房节前α₂和β肾上腺素能受体的影响。当未预处理大鼠的心房用(³H)-去甲肾上腺素预孵育时,(-)-异丙肾上腺素(0.02至4.0微摩尔)不影响刺激心脏加速神经引起的氚溢出,但较高浓度(40微摩尔)会使其降低。育亨宾(0.03、0.3和0.8微摩尔)阻断节前抑制性α₂肾上腺素能受体会增强氚的溢出。在育亨宾存在的情况下,异丙肾上腺素(1.2微摩尔)显著增加刺激诱导的递质溢出,表明在大鼠心房中,异丙肾上腺素通过节前β肾上腺素能受体介导的促进作用被抑制性α₂肾上腺素能受体的主导影响所掩盖。(-)-普萘洛尔(0.1微摩尔)在育亨宾(0.3微摩尔)存在时可防止异丙肾上腺素引起的心房率增加和异丙肾上腺素诱导的递质释放增强,但本身并不改变刺激诱导的氚流出,表明神经释放的去甲肾上腺素未能激活促进性节前β肾上腺素能受体。当用克伦特罗预处理大鼠的心房用³H-去甲肾上腺素预孵育时,0.03和0.3微摩尔育亨宾的促进作用明显增强,在这种情况下,异丙肾上腺素(1.2和12.0微摩尔)在α₂肾上腺素能受体拮抗剂存在时未能产生其促进作用。普萘洛尔不改变育亨宾的促进作用。在克伦特罗处理的大鼠中,未观察到异丙肾上腺素引起的心房率增加有变化。(摘要截断于250字)